Nuclear access
Help therapeutic DNA reach the nucleus by using delivery designs that are compatible with the cell’s internal transport architecture.
Inlet Bio
Programmable delivery through cellular architecture.
Inlet Bio is developing nonviral delivery systems designed to help genetic medicines move through the cell, reach the nucleus, and support durable activity without viral capsids or genome integration.
The bottleneck
DNA medicines need better intracellular delivery.
Many genetic medicines can be designed quickly, but delivery remains the central challenge. For durable DNA-based therapies, the payload must do more than enter a cell. It must survive transit, reach the right intracellular compartment, stay active, and avoid triggering excessive innate immune alarm.
Inlet Bio is focused on that delivery problem: making nonviral DNA delivery more programmable, durable, and redosable.
Platform thesis
Delivery should be engineered around the architecture of the cell.
Our platform is built around three high-level design layers that address the major intracellular barriers for nonviral DNA medicines.
Durable episomal activity
Support useful gene expression from non-integrating DNA that remains outside the genome.
Immune-aware delivery
Design payloads and particles to reduce unnecessary inflammatory sensing and support the potential for repeat administration.
What makes it different
A systems view of nonviral genetic delivery.
Rather than optimizing only the DNA sequence, only the particle, or only the immune profile, Inlet Bio treats delivery as a linked system.
Move
Design the payload-particle system to move through cellular barriers more effectively.
Arrive
Favor delivery to the intracellular location where DNA can become useful.
Remain active
Support durable expression without relying on viral capsids or genome integration.
Stay quiet
Balance expression with immune tolerability to enable practical therapeutic dosing.
Pipeline focus
Three candidate asset lanes.
Inlet Bio is organizing its platform around three high-level product directions where durable, redosable, nonviral DNA delivery could matter most.
A
Secreted protein replacement
DNA payloads intended to help target tissues produce useful therapeutic proteins over time.
B
Local tissue delivery
Programs aimed at accessible tissues where repeat local dosing and immune tolerability are important.
C
Cell-based applications
Approaches for cells handled outside the body, where delivery, activity, and cell health can be measured before use.
Contact
Connect with Inlet Bio.
For partnering, scientific, or company inquiries, please reach out by email. We welcome conversations with collaborators, advisors, and prospective partners.
info@inletbio.comEmail is the best way to reach the company for introductions, partnering discussions, and scientific interest.
867 Boylston St
Suite 500 Unit #1482
Boston, MA 02116